Trial Profile
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Intravenous Doses of BI 655130 (Double-blind, Partially Randomised Within Dose Groups, Placebo-controlled Parallel Group Design) and One Single Intravenous Dose of BI 655130 (Single-blind, Partially Randomised, Placebo-controlled) in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Spesolimab (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 01 Dec 2022 Results from Phase I Clinical Studies ( NCT02525679, NCT02852824, NCT03100903, NCT03123094, NCT03617835 ) assessing pharmacokinetics of spesolimab and evaluate changes with respect to dose, frequency of dosing, formulation and injection site. Immunogenicity, safety and tolerability published in the Clinical Pharmacokinetics
- 22 Aug 2017 Status changed from active, no longer recruiting to completed.
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.